CCR2 is predominantly expressed by monocytes/macrophages with strong proinflammatory
functions, prompting the development of CCR2 antagonists to dampen unwanted immune …

The CCL2 chemokine receptor CCR2 drives cancer by mediating the recruitment of
monocytes and myeloid-derived suppressor cells to the tumor microenvironment. In this …

The therapeutic efficacy of anthracyclines relies, at least partially, on the induction of a
dendritic cell–and T-lymphocyte–dependent anticancer immune response. Here, we show …

Highlights•A limited number of chemokines direct the polarization of CD4+ and CD8+ T
cells.•The CXCL10 is a driver chemokine of effector CD4+ and CD8+ T cells.•CXCL10 …

The tumor-promoting potential of CCL5 has been proposed but remains poorly understood.
We demonstrate here that an autocrine CCL5–CCR5 axis is a major regulator of …

Monocyte chemoattractant protein-1 (MCP-1/CCL2) is renowned for its ability to drive the
chemotaxis of myeloid and lymphoid cells. It orchestrates the migration of these cell types …

Immune responses against cancer rely upon leukocyte trafficking patterns that are
coordinated by chemokines. CCR5, the receptor for chemotactic chemokines MIP1alpha …

In addition to direct effect on tumor cells, the tumor-promoting activity of CCL2 has been
ascribed to its role in chemoattracting tumor-associated macrophages. However it is unclear …

The chemokine ligand CCL2 and its receptor CCR2 are implicated in the initiation and
progression of various cancers. CCL2 can activate tumour cell growth and proliferation …

Within the tumor microenvironment, chemokines play a key role in immune cell trafficking
regulation and immune landscape formulation. CCL3 or macrophage inflammatory protein …